With our complex set of analyses, we not only addressed morphological, molecular, and immunological aspects of advanced HNSCC, but also identified CDK4 gains as a new “surrogate” marker for abemaciclib response and describe a personalized approach to conquer intrinsic CDKI resistance. The gene discussed is CDK4; the disease is head and neck squamous cell carcinoma.